<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842162</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002442-20</org_study_id>
    <secondary_id>2019/2886</secondary_id>
    <nct_id>NCT04842162</nct_id>
  </id_info>
  <brief_title>Study Evaluating Near-infrared Imaging Coupled With Indocyanin Green for Intraoperative Control of Resection Margins in ENT Surgery</brief_title>
  <acronym>MAGNOLIA</acronym>
  <official_title>Study Evaluating Near-infrared Imaging Coupled With Indocyanin Green for Intraoperative Control of Resection Margins in ENT Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic&#xD;
      residual disease in the operating room after a complete macroscopic surgical resection of&#xD;
      head and neck cancers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective non-randomized bicentric study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Near Infrared Fluorescence Imaging</measure>
    <time_frame>at surgery</time_frame>
    <description>Sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after complete macroscopic surgical resection.&#xD;
For the calculation of the sensitivity, for each operating room we consider the first section and the last section in which the pathological analysis confirms the presence of microscopic residual disease. Patients for whom near-infrared fluorescence imaging detects disease are classified as true positives (TP). Sensitivity is defined as the number of TP divided by the total number of patients N.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with head and neck cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green</intervention_name>
    <description>indocyanine green (INFRACYANINEÂ© 25mg/10mL.[SERB - 40, avenue George V - 75008 Paris, France]).</description>
    <arm_group_label>Patients with head and neck cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 years of age or older&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Histological confirmation of squamous cell carcinoma&#xD;
&#xD;
          -  Locating the primary tumour in the oral cavity or oropharynx&#xD;
&#xD;
          -  Disease operable for complete resection&#xD;
&#xD;
          -  Serum or urinary pregnancy test (as per centre practices) negative within 14 days&#xD;
             prior to systemic indocyanin green injection (pre-operative visit), for women of&#xD;
             childbearing age&#xD;
&#xD;
          -  Patient information and signed free and informed consent&#xD;
&#xD;
          -  Patient affiliated with a social security scheme or beneficiary of a similar scheme.&#xD;
&#xD;
          -  The patient must understand, sign and date the consent form prior to any&#xD;
             protocol-specific procedures. The patient must be able and willing to comply with the&#xD;
             study visits and procedures described in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe medical co-morbidities or contraindications to surgery&#xD;
&#xD;
          -  Primary tumour not operable&#xD;
&#xD;
          -  History of head and neck cancer in the past 5 years&#xD;
&#xD;
          -  History of radiation for head and neck cancer&#xD;
&#xD;
          -  Metastatic cancer&#xD;
&#xD;
          -  Tumours with necrosis ranges in pre-operative imaging&#xD;
&#xD;
          -  History of invasive cancer unless there has been no recurrence for more than 5 years&#xD;
             with an exception for non-melanoma skin cancers.&#xD;
&#xD;
          -  Pregnant or nursing woman&#xD;
&#xD;
          -  Allergy or hypersensitivity to the product being administered (its active substance or&#xD;
             other ingredients), iodized products or crustaceans.&#xD;
&#xD;
          -  Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of&#xD;
             autoimmune origin.&#xD;
&#xD;
          -  Documented coronary artery disease&#xD;
&#xD;
          -  Advanced renal failure (creatinine &gt; 1,5mg/dL).&#xD;
&#xD;
          -  Within 2 weeks prior to inclusion, concomitant medication that reduces or increases&#xD;
             extinction of GI (i.e. anticonvulsants, haloperidol and Heparin).&#xD;
&#xD;
          -  Patient under guardianship or curatorship or deprived of liberty by judicial or&#xD;
             administrative decision or patient unable to give consent.&#xD;
&#xD;
          -  Patients unable to undergo medical follow-up of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Gorphe, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.gorphe@gustaveroussy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Gorphe, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.gorphe@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thibaud Motreff</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>thibaud.motreff@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

